High-dose probiotics for the treatment of active pouchitis
High-dose probiotics for the treatment of active pouchitis
复制标题
DOI：
10.1007/s10350-007-9068-4
复制
发表时间：
2007-12-01
影响因子：
3.9
通讯作者：
Campieri, Massimo
中科院分区：
文献类型：
--
作者：
Gionchetti, Paolo;Rizzello, Fernando;Campieri, Massimo
目的：储袋炎是溃疡性结肠炎回肠储袋肛管吻合术后主要的长期并发症。广谱抗生素是这种情况的主要治疗方法。最近，我们展示了高浓缩益生菌制剂（VSL#3，9000 亿/袋冻干活菌）在预防慢性储袋炎复发和预防储袋炎发作方面的功效。本研究旨在评估高剂量 VSL#3 治疗轻度活动性储袋炎的疗效。 方法：连续 23 名患有轻度活动性储袋炎的患者（定义为储袋炎疾病活动指数得分在 7 至 12 之间，包括临床、内窥镜和组织学标准）接受 VSL#3 治疗，每天两次，每次 2 包。 （36000 亿个细菌/天）持续四个星期。根据贮袋炎疾病活动指数在治疗前后进行症状、内镜和组织学评估。缓解被定义为贮袋炎疾病活动指数临床评分的组合
PURPOSE: Pouchitis is the major long-term complication after ileal-pouch anal anastomosis for ulcerative colitis. Broad-spectrum antibiotics are the mainstay of treatment in this condition. Recently, we have shown the efficacy of a highly concentrated probiotic preparation (VSL#3, 900 billions/sachet lyophilized viable bacteria) in preventing relapses of chronic pouchitis and in preventing pouchitis onset. This study was designed to evaluate the efficacy of high-dose VSL#3 in the treatment of mildly active pouchitis.METHODS: Twenty-three consecutive patients with mild pouchitis, defined as a score of between 7 and 12 in the Pouchitis Disease Activity Index, which includes clinical, endoscopic, and histological criteria, were treated with VSL#3, 2 sachets b.i.d. (3600 billion bacteria/day) for four weeks. Symptomatic, endoscopic, and histologic evaluations were undertaken before and after treatment according to Pouchitis Disease Activity Index. Remission was defined as a combination of a Pouchitis Disease Activity Index clinical score of